Table 3. Association with Mayo CBD cohort and SNPs at MOBP predicted to be in regulatory enhancer regions.
| SNP | Gene | CBD MAF | Control MAF | LD R2 rs1768208* | OR (95% CI) | P |
|---|---|---|---|---|---|---|
| rs631312 | MOBP (Upstream) | 0.39 | 0.25 | 0.84 | 1.89 (1.30–2.75) | 8.77 × 10−4 |
| rs1768190 | MOBP (Intron 1) | 0.40 | 0.26 | 0.78 | 1.91 (1.31–2.77) | 7.24 × 10−4 |
| rs1768208 | MOBP (Intron 2) | 0.40 | 0.29 | — | 1.89 (1.28–2.77) | 1.27 × 10−3 |
Mayo CBD cohort is composed of 133 autopsy-proven CBD cases and were tested for association with 457 controls from the replication stage. Association testing was performed using logistic regression under an additive model, with age and sex as covariates.
*Linkage disequilibrium (LD) values from HapMap release 27 with top MOBP SNP associated with CBD, rs1768208 (Meta-analysis results, OR=1.71, Pmeta=2.07 × 10−7).